mRNA Lipid Nanoparticles for <i>Ex Vivo</i> Engineering of Immunosuppressive T Cells for Autoimmunity Therapies.

Thatte, Ajay S; Hamilton, Alex G; Nachod, Benjamin E; Mukalel, Alvin J; Billingsley, Margaret M; Palanki, Rohan; Swingle, Kelsey L; Mitchell, Michael J · Nano Lett · 2023

basic_science · Level V

Where this comes from

Abstract

Cell-based therapies for autoimmune diseases have gained significant traction, with several approaches centered around the regulatory T (T<sub>reg</sub>) cell─a well-known immunosuppressive cell characterized by its expression of the transcription factor Foxp3. Unfortunately, due to low numbers of T<sub>reg</sub> cells available in circulation, harvesting and culturing T<sub>reg</sub> cells remains a challenge. It has been reported that engineering Foxp3 expression in CD4<sup>+</sup> T cells can result in a T<sub>reg</sub>-like phenotype; however, current methods result in the inefficient engineering of these cells. Here, we develop an ionizable lipid nanoparticle (LNP) platform to effectively deliver Foxp3 mRNA to CD4<sup>+</sup> T cells. We successfully engineer CD4<sup>+</sup> T cells into Foxp3-T (FP3T) cells that transiently exhibit an immunosuppressive phenotype and functionally suppress the proliferation of effector T cells. These results demonstrate the promise of an LNP platform for engineering immunosuppressive T cells with potential applications in autoimmunity therapies.

Medical subject headings